CIBC Capital Markets maintained its outperformer rating on the shares of kneat.com (KSI.TO) and raised its price target to C$6.25 from C$5.50 after the company confirmed that it started a strategic in February 2026 to explore potential strategic options.
The bank sees kneat as "attractive" for both strategic and financial buyers, given its "leading position in digital validation software for regulated industries (used by eight of the world's top 10 pharmaceutical manufacturers) and strong recurring revenue growth (~$74MM ARR, +33% Y/Y SaaS revenue in 2025)".
"With strategic optionality now adding upside potential, we maintain our Outperformer rating on Kneat, and we have adjusted our valuation approach to blend our standalone intrinsic value with a scenario-weighted takeout value, resulting in a price target of $6.25 ($5.50 prior)," said analyst Erin Kyle. "We agree that ArisGlobal and Blue Mountain, which both serve major pharma customers would be logical bidders in terms of product fit and customer base."
The bank also expects management to have a preference for an acquirer with experience scaling software and familiarity with the life sciences space, in a scenario where kneat decides to sell itself.
"Given Kneat's high gross margin and mission-critical software, we could see a scenario where a higher-than-average premium (40%-50%) is offered, resulting in 8.3x sales or $6.75/sh," said Kyle.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $5.30, Change: $+0.03, Percent Change: +0.57%